FDA clears Xcision's breast cancer radiotherapy device
Medical technology company Xcision Medical Systems has received 510(k) clearance...Read more on AuntMinnie.com
Authors: Rafael D, Gener P, Andrade F, Seras-Franzoso J, Montero S, Fernández Y, Hidalgo M, Arango D, Sayós J, Florindo HF, Abasolo I, Schwartz S, Videira M Abstract Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that ...
Condition: Breast Cancer Female Intervention: Other: No intervention Sponsors: Trisakti University; Dharmais National Cancer Center Hospital Recruiting
Conditions: Primary Invasive Breast Cancer; Estrogen Receptor Positive Tumor; Human Epidermal Growth Factor Receptor 2 Negative Tumor Intervention: Other: Observation Sponsors: North Eastern Germany Society of Gynaecologic Oncology; Center for Clinical Trials Philipps University Marburg Not yet recruiting
Almost 10,000 women a year are to benefit from NHS breast cancer tests that could spare them the stress of chemotherapy after a U-turn by Nice.
The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of mole...
We examined the degree to which persistent breast pain and experience as a cancer caregiver were related to cancer worry and perceived risk in first-degree relatives of women with breast cancer (N = 85) and how catastrophic thoughts about breast pain could impact these relationships. There was a significant interaction between persistent breast pain and pain catastrophizing in predicting cancer worry (p = .03); among women who engaged in pain catastrophizing, cancer worry remained high even in the absence of breast pain. Pain catastrophizing also moderated the relationships between caregiving in...
To compare the value of dynamic contrast-enhanced magnetic resonance imaging-pharmacokinetic (PK) parameters vs tumor volume in predicting breast cancer neoadjuvant chemotherapy response (NACR) and patient survival.
In conclusion, our data suggest that MAGI2-AS3 expression is decreased in breast cancer and that MAGI2-AS3 plays an important role as a tumour suppressor by targeting Fas and FasL signalling. These results provide new insight into novel clinical treatments for breast cancer.